184 related articles for article (PubMed ID: 8782176)
21. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues.
Wang SC; Wikström MG; White DL; Klaveness J; Holtz E; Rongved P; Moseley ME; Brasch RC
Radiology; 1990 May; 175(2):483-8. PubMed ID: 1691513
[TBL] [Abstract][Full Text] [Related]
22. Gd-DTPA L-cystine bisamide copolymers as novel biodegradable macromolecular contrast agents for MR blood pool imaging.
Kaneshiro TL; Ke T; Jeong EK; Parker DL; Lu ZR
Pharm Res; 2006 Jun; 23(6):1285-94. PubMed ID: 16729223
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and in vivo evaluation of a self-assembled gadolinium(III)-iron(II) contrast agent with high relaxivity.
Parac-Vogt TN; Vander Elst L; Kimpe K; Laurent S; Burtéa C; Chen F; Van Deun R; Ni Y; Muller RN; Binnemans K
Contrast Media Mol Imaging; 2006; 1(6):267-78. PubMed ID: 17191767
[TBL] [Abstract][Full Text] [Related]
24. A macromolecular contrast agent for magnetic resonance imaging. Effect of molecular weight on blood pharmacokinetics and enhancement patterns for polylysine-gadopentetate dimeglumine.
Vexler VS; Clément O; Brasch RC
Invest Radiol; 1994 Jun; 29 Suppl 2():S62-4. PubMed ID: 7928273
[No Abstract] [Full Text] [Related]
25. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
26. Quantification of capillary permeability to macromolecular magnetic resonance imaging contrast media in experimental mammary adenocarcinomas.
Brasch RC; Shames DM; Cohen FM; Kuwatsuru R; Neuder M; Mann JS; Vexler V; Mühler A; Rosenau W
Invest Radiol; 1994 Jun; 29 Suppl 2():S8-11. PubMed ID: 7928277
[No Abstract] [Full Text] [Related]
27. A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution.
Demsar F; Roberts TP; Schwickert HC; Shames DM; van Dijke CF; Mann JS; Saeed M; Brasch RC
Magn Reson Med; 1997 Feb; 37(2):236-42. PubMed ID: 9001148
[TBL] [Abstract][Full Text] [Related]
28. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A.
Erstad DJ; Ramsay IA; Jordan VC; Sojoodi M; Fuchs BC; Tanabe KK; Caravan P; Gale EM
Invest Radiol; 2019 Nov; 54(11):697-703. PubMed ID: 31356382
[TBL] [Abstract][Full Text] [Related]
29. Contrast-enhanced MRI of tumors. Comparison of Gd-DTPA and a macromolecular agent.
Wikström MG; Moseley ME; White DL; Dupon JW; Winkelhake JL; Kopplin J; Brasch RC
Invest Radiol; 1989 Aug; 24(8):609-15. PubMed ID: 2777530
[TBL] [Abstract][Full Text] [Related]
30. The effects of gadolinium-DTPA and -DOTA on neural tissue metabolism.
Morris TW; Ekholm SE; Prentice LI
Invest Radiol; 1991 Dec; 26(12):1087-90. PubMed ID: 1765443
[TBL] [Abstract][Full Text] [Related]
31. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool and perfusion imaging.
Schmiedl U; Brasch RC; Ogan MD; Moseley ME
Acta Radiol Suppl; 1990; 374():99-102. PubMed ID: 1966977
[TBL] [Abstract][Full Text] [Related]
32. Comparison of gadolinium-DTPA and polylysine-gadolinium-DTPA--enhanced magnetic resonance imaging of hepatocarcinoma in the rat.
Grandin C; Van Beers BE; Demeure R; Goudemant JF; Mottet I; Pringot J
Invest Radiol; 1995 Oct; 30(10):572-81. PubMed ID: 8557496
[TBL] [Abstract][Full Text] [Related]
33. Mannan-coated liposome delivery of gadolinium-diethylenetriaminepentaacetic acid, a contrast agent for use in magnetic resonance imaging.
Kunimasa J; Inui K; Hori R; Kawamura Y; Endo K
Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2565-7. PubMed ID: 1446380
[TBL] [Abstract][Full Text] [Related]
34. A new biodegradable and biocompatible gadolinium (III) -polymer for liver magnetic resonance imaging contrast agent.
Xiao Y; Xue R; You T; Li X; Pei F
Magn Reson Imaging; 2015 Jul; 33(6):822-8. PubMed ID: 25839395
[TBL] [Abstract][Full Text] [Related]
35. Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats.
Mühler A; Heinzelmann I; Weinmann HJ
Invest Radiol; 1994 Feb; 29(2):213-6. PubMed ID: 8169100
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
Oudkerk M; Sijens PE; Van Beek EJ; Kuijpers TJ
Invest Radiol; 1995 Feb; 30(2):75-8. PubMed ID: 7782190
[TBL] [Abstract][Full Text] [Related]
37. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.
Tofts PS
J Magn Reson Imaging; 1997; 7(1):91-101. PubMed ID: 9039598
[TBL] [Abstract][Full Text] [Related]
38. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model.
Tofts PS; Berkowitz B; Schnall MD
Magn Reson Med; 1995 Apr; 33(4):564-8. PubMed ID: 7776889
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary oxygen toxicity: demonstration of abnormal capillary permeability using contrast-enhanced MRI.
Brasch RC; Berthezène Y; Vexler V; Rosenau W; Clément O; Mühler A; Kuwatsuru R; Shames DM
Pediatr Radiol; 1993; 23(7):495-500. PubMed ID: 8309747
[TBL] [Abstract][Full Text] [Related]
40. Angiographic properties of Gd-DTPA-24-cascade-polymer--a new macromolecular MR contrast agent.
Schwickert HC; Roberts TP; Mühler A; Stiskal M; Demsar F; Brasch RC
Eur J Radiol; 1995 Jul; 20(2):144-50. PubMed ID: 7588870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
